Schilder's disease is a dubious disease in the field of the nervous system, with complex clinical outcomes that often involve multi-system congestion. Early identification and normalisation of clinical trials are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological evaluations.
The platform can assist in bringing together a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment and management of Schilder's disease require the development of a multi-dimensional treatment plan, usually including drug therapy, rehabilitation interventions, and regular follow-up. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many formerly difficult-to-treat neurological disorders have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, and timely adjusted according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of Schilder disease. The platform serves a team of nationally and internationally authoritative experts in the field of neural systems aligned with the International Medical Service System of China, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.